Welcome to our blog dedicated to Life Sciences. We report on EU and national regulatory, compliance, intellectual property and transactional developments in the sector. We focus on (bio)pharmaceuticals and medical technologies, and also cover food and beverages, cosmetics and other healthcare products.

Brexit: EMA’s regulatory guidance on centrally approved medicinal products – the present state of play

Jacqueline Bore

The champagne bottles have been drained in Amsterdam and tears dried in Milan and Bratislava but the serious work of mapping out the practical implications of Brexit continues at the European Medicines Agency (EMA). The EMA and the European Commission issued a Notice in May 2017 confirming that “unless the withdrawal agreement establishes another date” Read More

Suppliers of luxury goods can restrict online sales on (discernible) third-party platforms, says the Court of Justice

Florence Ninane

The European Court of Justice (ECJ) handed down yesterday its much awaited ruling in Coty Germany GmbH (C-230/16). It has clarified that a supplier of luxury goods can include a clause in selective distribution agreements prohibiting authorised distributors from selling those goods through non-authorised third-party platforms in a discernible manner, in order to preserve the Read More

European Commission clarifies framework applicable to food for special medical purposes

Patricia Carmona Botana

The European Commission recently published a Notice on the classification of Food for Special Medical Purposes (FSMP) that provides guidance to companies and national regulators on the legal framework applicable to FSMP and on the criteria that are required to classify a product as a FSMP (Notice). The Notice confirms that FSMP is in principle food Read More

Dutch Minister to explore possibility of compulsory licenses and pharmacy preparations

Anna-Maria Withagen

The Dutch Minister of Medical Care, Bruno Bruins, announced that he is going to explore the possibility of granting compulsory licenses in order to make pharmaceutical companies lower the prices of certain medicines they offer. During a debate, Bruins said that, although the instrument has not been used in the previous years, this does not Read More

Pension funds to catalyse growth in Life Sciences companies?

Matthew Appleton

We’ve seen a lot of activity in the past week around how the UK government plans to galvanise growth in innovative companies (summary here). As I wrote a couple of months ago, only by focusing on all stages in the growth cycle of a Life Sciences company can four £20bn+ UK companies be created in Read More